The Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca's BEYFORTUS (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and ...

Beyfortus is not known to interact with other medications, herbs, supplements, foods, or alcohol. The manufacturer of Beyfortus didn’t look at interactions in studies of the drug.

Beyfortus won FDA approval in July as a passive immunization for RSV-related lower respiratory tract disease in newborns and infants born during or entering their first RSV season, plus young kids ...

BEYFORTUS administration can be timed to coincide with the RSV season. BEYFORTUS has been approved for use in the US, the European Union, China, Japan, and many other countries around the world.

Experts say Beyfortus, a new injectable monoclonal antibody that protects kids from RSV, will be critical ahead of cold and flu season. Here’s how it works.

The second trial included 1490 term and late-preterm infants, of which 994 received Beyfortus; 1.2% of infants on Beyfortus were infected with MA RSV LRTI vs 5.0% in the placebo group.

Sanofi has tripled Beyfortus production and doubled manufacturing sites since its 2023 launch. PPI and Industrial Production drop Wednesday morning — see how Matt Maley is trading the reaction ...

"Beyfortus is a shot given to babies, and it protects 'em against RSV," Dr. Eliza Varadi said. Read more: "South Carolina health department urges flu vaccinations during National Flu Vaccine Week." ...

BEYFORTUS is a long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and ...

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial ...

The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...